A collaboration with Mayo Clinic BioPharma Diagnostics includes access to the neurologic disease testing capabilities of Mayo Clinic Laboratories. Our highly specialized neurology testing menu features more than 400 neurologist-backed...
The birth of Mayo Clinic Laboratories: From tiny operation to international mainstay - Insights
In 1971, the Regional Laboratory, later to become Mayo Clinic Laboratories, was founded. For the first time in Mayo Clinic’s history, the institution would support the community practice of pathology for outside patients in the region and...
The evolution of specimen accessioning and delivery - Insights
The last installment of our 50th Anniversary series explores how Mayo Clinic Laboratories pioneered best practices in the area of specimen accessioning and delivery.
A novel testing approach for newly identified VEXAS syndrome - Insights
VEXAS syndrome is a severe autoinflammatory disease that results in a spectrum of rheumatologic and hematologic conditions. The underlying cause of newly identified VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome —...
What started as a persistent headache for Spencer Lodin soon devolved into slowed speech, seizures, and hallucinations, symptoms which stumped ER doctors into thinking he had meningitis or was suffering from psychosis. Finally, specialized...
Synthesizing cardiovascular genetic test results into a unified diagnosis for the patient - Insights
For over two decades, Mayo Clinic has been at the forefront of cardiovascular (CV) genetic testing. The current test menu features 24 different panels that span over 300 genes linked to inherited cardiovascular disorders, many of which are...
Heartbeats of gratitude: Scott Olson - Insights
In a quiet suburb outside of Minneapolis, Minnesota, an ordinary Saturday took a sudden and alarming turn for Scott Olson when he began experiencing symptoms of ventricular tachycardia. Central to the care and treatment he'd receive at Mayo...
Since 1992, cases of colorectal cancer have been on a slow decline, yet 52,550 people died from it in 2023. At Mayo Clinic, a cutting-edge menu of both germline (inherited genetic alterations) and somatic (tumors due to non-inherited...
Unveiling a novel hemoglobinopathy classification - Insights
In a recent discovery by Mayo Clinic Laboratories, a novel hemoglobinopathy category was identified and termed epsilon gamma thalassemia. The first instance of the disorder was found in 2017 when an obstetric patient underwent a routine...
Hereditary testing by specialty - Insights
Mayo Clinic Laboratories is a one-stop laboratory for hereditary testing, featuring a robust menu of molecular, cytogenic, biochemical, and functional assays that support diagnosis and care.